AI-CVD vs Tempus ECG-AF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AI-CVD

by HeartLung AI

Tempus ECG-AF

by Tempus AI, Inc.

AI Verdict

AI-CVD focuses on opportunistic screening for broad cardiovascular and multisystem diseases using existing CT scans to provide quantitative imaging measurements. In contrast, Tempus ECG-AF analyzes 12-lead ECG recordings to identify patients at increased risk of developing atrial fibrillation/flutter. While both are cardiology AI tools, their distinct input modalities and specific disease targets make them complementary rather than directly competitive.

Choose AI-CVD if…

Choose AI-CVD if your institution frequently performs chest and abdominal CT scans for various indications and you aim to opportunistically screen for a broad range of hidden cardiovascular and multisystem disease risks without additional imaging or workflow disruption. This platform is ideal for leveraging existing imaging data to identify conditions like coronary artery calcium, aortic valve calcification, and abnormal cardiac chamber volumes in a comprehensive manner.

View AI-CVD →

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your primary goal is to proactively identify elderly patients (65+) at increased risk of developing new-onset atrial fibrillation/flutter within the next 12 months, utilizing standard 12-lead ECG recordings. This solution is best suited for integrating into cardiology or internal medicine workflows to support earlier identification and follow-up for AF risk in a specific patient demographic.

View Tempus ECG-AF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AI-CVD	Tempus ECG-AF
Pricing	Unknown	Contact vendor
Deployment	Unknown	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.
BAA Available	Yes AI-estimated	Yes AI-estimated
FDA Status	Cleared AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AI-CVD	Tempus ECG-AF
Name	AI-CVD	Tempus ECG-AF
Company	HeartLung Corporation	Tempus AI, Inc.
Primary Input Data	Existing CT scans (chest and abdominal)	12-lead ECG recordings
Target Condition/Screening Focus	Opportunistic screening for cardiovascular and multisystem diseases, early detection of hidden health risks.	Identify patients at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.
Target Patient Population	Not specified	Patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.
Key Feature (Example)	Coronary Artery Calcium (CAC) scoring	AI-based algorithm for 12-lead ECG analysis
Specialties	Cardiology, Pulmonology, Radiology	Cardiology, Geriatrics, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring AI-CVD and Tempus ECG-AF.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary differences in the types of conditions these tools are designed to detect?

AI-CVDu00ae is an AI-powered quantitative imaging platform that performs opportunistic screening for cardiovascular and multisystem diseases using existing CT scans, including Coronary Artery Calcium (CAC) scoring, aortic calcification, and cardiac chamber volumetry. Tempus ECG-AF is an AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.

What type of patient data or imaging is required for each tool?

AI-CVDu00ae utilizes existing chest and abdominal CT scans for its analysis, requiring no additional imaging, radiation, contrast, or workflow disruption. Tempus ECG-AF analyzes standard 12-lead ECG recordings collected at a healthcare facility.

For which patient populations are these tools intended?

AI-CVDu00ae is designed for opportunistic screening from existing CT scans, enabling early detection of hidden health risks in a broad population undergoing CTs for other reasons. Tempus ECG-AF is specifically intended for patients aged 65 or older who do not have a known history of AF, pacemakers, ICDs, or recent cardiac surgery.

How do these tools integrate into a physician's existing workflow?

AI-CVDu00ae integrates by performing opportunistic screening from existing CT scans without requiring additional imaging, radiation, contrast, or workflow disruption. Tempus ECG-AF is a software solution designed to be integrated into healthcare facility systems with advanced cardiology algorithms, analyzing 12-lead ECGs.

What specific measurements or insights does each tool provide?

AI-CVDu00ae provides automated CT-derived anatomical and density-based measurements, including Coronary Artery Calcium (CAC) scoring, aortic wall and valve calcium analysis, cardiac chamber volumetry, epicardial fat volumetry, and aorta and pulmonary artery sizing. Tempus ECG-AF uses an AI-based algorithm to detect signs associated with a patient experiencing new onset Atrial Fibrillation (AF) within the next 12 months.

Is there a reimbursement pathway for either of these tools?

For AI-CVDu00ae, pricing information requires contacting the vendor, and no specific reimbursement pathway is mentioned. Tempus ECG-AF has CMS reimbursement available, with CPT codes 0764T and 0765T assigned to APC 5734, at a Medicare rate of $128.90, effective January 1, 2025.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform